<http://schema.org/description>
"On September 12, 2011, RXi Pharmaceuticals Corporation (RXII) announced a clinical trial update on its lead program, NeuVax (E75 peptide vaccine with GM-CSF adjuvant), a cancer immunotherapy targeted for low-to-intermediate HER2 expressing breast cancer patients not eligible for trastuzamab (Herceptin)."^^<http://www.w3.org/2001/XMLSchema#string>
<https://www.zacks.com/stock/news/60642/fda-lifts-hold-on-rxi-breast-cancer-vaccine-trial>